{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:17:30Z","timestamp":1770635850082,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1047105"],"award-info":[{"award-number":["1047105"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fremantle Hospital Medical Research Foundation","award":["2014"],"award-info":[{"award-number":["2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00228-018-2597-z","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T22:28:35Z","timestamp":1543876115000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations"],"prefix":"10.1007","volume":"75","author":[{"given":"Jonathan","family":"Chambers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Page-Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M. E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"issue":"5","key":"2597_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.coph.2007.08.003","volume":"7","author":"F Perez","year":"2007","unstructured":"Perez F, Endimiani A, Hujer KM, Bonomo RA (2007) The continuing challenge of ESBLs. Curr Opin Pharmacol 7(5):459\u2013469. \n                    https:\/\/doi.org\/10.1016\/j.coph.2007.08.003","journal-title":"Curr Opin Pharmacol"},{"issue":"9498","key":"2597_CR2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(05)67694-5","volume":"366","author":"BA Lipsky","year":"2005","unstructured":"Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA (2005) Ertapenem versus piperacillin\/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366(9498):1695\u20131703. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)67694-5","journal-title":"Lancet"},{"key":"2597_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/1756-0500-4-478","volume":"4","author":"ND Goswami","year":"2011","unstructured":"Goswami ND, Johnson MD, Chu VH (2011) Ertapenem for treatment of osteomyelitis: a case series. BMC Res Notes 4:478. \n                    https:\/\/doi.org\/10.1186\/1756-0500-4-478","journal-title":"BMC Res Notes"},{"issue":"4","key":"2597_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/AAC.50.4.1222-1227.2006","volume":"50","author":"M Chen","year":"2006","unstructured":"Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr (2006) Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50(4):1222\u20131227. \n                    https:\/\/doi.org\/10.1128\/AAC.50.4.1222-1227.2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2597_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/507543","volume":"43","author":"HM Nijland","year":"2006","unstructured":"Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43(7):848\u2013854. \n                    https:\/\/doi.org\/10.1086\/507543","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2597_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F (2009) Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 48(2):89\u2013124. \n                    https:\/\/doi.org\/10.2165\/0003088-200948020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2597_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jac\/dkm296","volume":"60","author":"E Boselli","year":"2007","unstructured":"Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B (2007) Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother 60(4):893\u2013896. \n                    https:\/\/doi.org\/10.1093\/jac\/dkm296","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2597_CR8","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","volume":"46","author":"AK Majumdar","year":"2002","unstructured":"Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, Rogers JD (2002) Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 46(11):3506\u20133511","journal-title":"Antimicrob Agents Chemother"},{"key":"2597_CR9","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2016) MIC distributions and ECOFFs. In: EUCAST (Ed.) ed."},{"issue":"2","key":"2597_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","volume":"58","author":"B Green","year":"2004","unstructured":"Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58(2):119\u2013133. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02157.x","journal-title":"Br J Clin Pharmacol"},{"key":"2597_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332. \n                    https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"2597_CR12","first-page":"1005","volume":"80","author":"T Borracci","year":"2014","unstructured":"Borracci T, Adembri C, Accetta G, Berti J, Cappellini I, Lucchese M, Biggeri A, De Gaudio AR, Novelli A (2014) Use of the parenteral antibiotic ertapenem as short term prophylaxis in bariatric surgery: a pharmaco-kinetic-pharmacodynamic study in class III obese female patients. Minerva Anestesiol 80(9):1005\u20131011","journal-title":"Minerva Anestesiol"},{"key":"2597_CR13","doi-asserted-by":"publisher","unstructured":"Wittau M, Paschke S, Kurlbaum M, Scheele J, Ly NS, Hemper E, Kornmann M, Henne-Bruns D, Bulitta JB (2017) Population pharmacokinetics and target attainment of ertapenem in plasma and tissue assessed via microdialysis in morbidly obese patients after laparoscopic visceral surgery. Antimicrob Agents Chemother 61 (1) \n                    https:\/\/doi.org\/10.1128\/AAC.00952-16","DOI":"10.1128\/AAC.00952-16"},{"issue":"3","key":"2597_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1464-5491.2001.00460.x","volume":"18","author":"JT Raymakers","year":"2001","unstructured":"Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC (2001) The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 18(3):229\u2013234","journal-title":"Diabet Med"},{"issue":"2","key":"2597_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF01617045","volume":"9","author":"S Vuorisalo","year":"2000","unstructured":"Vuorisalo S, Pokela R, Satta J, Syrjala H (2000) Internal mammary artery harvesting and antibiotic concentrations in sternal bone during coronary artery bypass. Int J Angiol 9(2):78\u201381","journal-title":"Int J Angiol"},{"issue":"3","key":"2597_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000238414","volume":"32","author":"RJ Grimer","year":"1986","unstructured":"Grimer RJ, Karpinski MR, Andrews JM, Wise R (1986) Penetration of amoxycillin and clavulanic acid into bone. Chemotherapy 32(3):185\u2013191","journal-title":"Chemotherapy"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2597-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:06:17Z","timestamp":1575399977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2597-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2597-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This prospective, single group, longitudinal PK study of single-dose intravenous ertapenem was approved by the Fremantle Hospital Human Research Ethics Committee (13\/4) and all patients gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}